ArticleOncogene2004
A novel E1A-E1B mutant adenovirus induces glioma regression in vivo.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L.Human gene therapy · 2022Article
- Review
- Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1.Gene therapy · 2021Article
- Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.PloS one · 2016Article
- Oncolytic adenoviruses: A thorny path to glioma cure.Genes & diseases · 2014Article
- Current Studies of Immunotherapy on Glioblastoma.Journal of neurology and neurosurgery · 2014Article
- Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.Frontiers in oncology · 2013Article
- HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.Molecular cancer · 2011Article
- Comparison of oncolytic adenoviruses for selective eradication of oral cancer and pre-cancerous lesions.Gene therapy · 2010Article
- Current issues and future directions of oncolytic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Review
- Viruses, gene therapy and stem cells for the treatment of human glioma.Cancer gene therapy · 2009Review
- Oncolytic viral therapy of malignant glioma.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2009Review
- E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.Cancer gene therapy · 2009Article
- Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes.Journal of virology · 2008Review
- The status of gene therapy for brain tumors.Expert opinion on biological therapy · 2007Review
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Genetic strategies for brain tumor therapy.Cancer gene therapy · 2006Review
- New delivery approaches for pediatric brain tumors.Journal of neuro-oncology · 2005Review
- Review
- An efficient construction of conditionally replicating adenoviruses that target tumor cells with multiple factors.Gene therapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Malignant gliomas are the most frequently occurring primary brain tumors and are resistant to conventional therapy. Conditionally replicating adenoviruses are a novel strategy in glioma treatment. Clinical trials using E1B mutant adenoviruses have been reported recently and E1A mutant replication-competent adenoviruses are in advanced preclinical testing. Here we constructed a novel replication-selective adenovirus (CB1) incorporating a double deletion of a 24 bp Rb-binding region in the E1a gene, and a 903 bp deleted region in the E1b gene that abrogates the expression of a p53-binding E1B-55 kDa protein. CB1 exerted a potent anticancer effect in vitro in U-251 MG, U-373 MG, and D-54 MG human glioma cell lines, as assessed by qualitative and quantitative viability assays. Replication analyses demonstrated that CB1 replicates in vitro in human glioma cells. Importantly, CB1 acquired a highly attenuated replicative phenotype in both serum-starved and proliferating normal human astrocytes. In vivo experiments using intracranially implanted D-54 MG glioma xenografts in nude mice showed that a single dose of CB1 (1.5 x 10(8) PFU/tumor) significantly improved survival. Immunohistochemical analyses of expressed adenoviral proteins confirmed adenoviral replication within the tumors. The CB1 oncolytic adenovirus induces a potent antiglioma effect and could ultimately demonstrate clinical relevance and therapeutic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.